

Mark S Sulkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422872/publications.pdf>

Version: 2024-02-01

246
papers

35,341
citations

8172

76
h-index

3260

185
g-index

248
all docs

248
docs citations

248
times ranked

19217
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 125-135.e8.	2.4	3
2	A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (<sc>HBV)–HIV</sc> co–infection with high prevalence of tenofovir–based antiretroviral therapy use. <i>HIV Medicine</i> , 2023, 24, 55-74.	1.0	2
3	HBV transcription and translation persist despite viral suppression in HBV–HIV co–infected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605.	3.6	2
4	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	2.4	34
5	Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. <i>Journal of Infectious Diseases</i> , 2022, 225, 903-911.	1.9	4
6	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	2.9	4
7	Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109177.	1.6	1
8	Machine learning algorithms for predicting direct–acting antiviral treatment failure in chronic hepatitis C: An HCV–TARGET analysis. <i>Hepatology</i> , 2022, 76, 483-491.	3.6	16
9	A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360) Tj ETQq1 1 0.784314 rgBT /Overlock 10 7, 307-317.	3.7	39
10	<i>Clostridioides difficile</i> infection (CDI) in a previous room occupant predicts CDI in subsequent room occupants across different hospital settings. <i>American Journal of Infection Control</i> , 2022, 50, 1352-1354.	1.1	5
11	Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
12	Sofosbuvir and risk of estimated glomerular filtration rate decline or end–stage renal disease in patients with renal impairment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1169-1178.	1.9	8
13	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	1.8	17
14	Safety and efficacy of vebicorvir administered with entecavir in treatment-na–ve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	1.8	21
15	Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	22
16	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	2.9	15
17	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant. <i>American Journal of Transplantation</i> , 2021, 21, 1780-1788.	2.6	14
18	Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C–Viremic Donors to Hepatitis C–Negative Recipients: An Open-Label Nonrandomized Study. <i>Annals of Internal Medicine</i> , 2021, 174, 137-138.	2.0	38

#	ARTICLE	IF	CITATIONS
19	Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. <i>Advances in Therapy</i> , 2021, 38, 423-440.	1.3	23
20	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	0
21	T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab079.	0.4	6
22	Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. <i>International Journal of Drug Policy</i> , 2021, 88, 103019.	1.6	7
23	Hepatitis B Virus/Hepatitis D Virus Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. <i>ACG Case Reports Journal</i> , 2021, 8, e00582.	0.2	3
24	Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1166-1187.	1.4	33
25	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	3.6	7
26	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV/HIV Coinfected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	3.6	11
27	Impact of co-occurring drug use, hazardous alcohol use and mental health disorders on drug use patterns in people living with HIV and hepatitis C virus infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab520.	0.4	0
28	Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. <i>Advances in Therapy</i> , 2021, 38, 5777-5790.	1.3	9
29	HCV communication within ego-centric networks of men and women who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109157.	1.6	4
30	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coinfected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	3.6	23
31	Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. <i>AJOB Empirical Bioethics</i> , 2020, 11, 40-52.	0.8	10
32	Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. <i>Lancet HIV</i> , 2020, 7, e443-e448.	2.1	27
33	Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs. <i>Journal of Viral Hepatitis</i> , 2020, 27, 476-483.	1.0	5
34	Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1462-1469.	1.9	18
35	Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2020, 27, 376-386.	1.0	9
36	Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1388-1395.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore. <i>BMC Infectious Diseases</i> , 2020, 20, 815.	1.3	9
38	Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. <i>Liver International</i> , 2020, 40, 2407-2416.	1.9	19
39	The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. <i>Advances in Therapy</i> , 2020, 37, 4709-4719.	1.3	5
40	DÃ©jà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failuresâ€”Same Satisfactory Results, Same Unanswered Questions. <i>Clinical Infectious Diseases</i> , 2020, 73, e3296-e3299.	2.9	0
41	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757.	1.9	9
42	Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1384-1396.	1.9	19
43	Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11987-11994.	3.3	15
44	Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virusâ€”HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. <i>Journal of Infectious Diseases</i> , 2020, 222, 1334-1344.	1.9	7
45	Individual and network factors associated with HCV treatment uptake among people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 78, 102714.	1.6	19
46	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. <i>Journal of Viral Hepatitis</i> , 2020, 27, 663-670.	1.0	18
47	Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. <i>Journal of Infectious Diseases</i> , 2020, 222, 601-610.	1.9	7
48	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990.	2.9	7
49	Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. <i>JCI Insight</i> , 2020, 5, .	2.3	17
50	Public Masking: An Urgent Need to Revise Global Policies to Protect against COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1160-1161.	0.6	12
51	The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 577-579.	2.9	4
52	THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders. <i>Journal of Hepatology</i> , 2019, 70, e242.	1.8	1
53	Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13194.	0.7	33
54	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , 2019, 157, 1506-1517.e1.	0.6	32

#	ARTICLE	IF	CITATIONS
55	Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. Open Forum Infectious Diseases, 2019, 6, ofz426.	0.4	14
56	The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry, 2019, , 97-113.	0.4	5
57	Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and Åÿ2M in the ION-4 Study Cohort. Open Forum Infectious Diseases, 2019, 6, ofy273.	0.4	9
58	Advanced liver fibrosis and care continuum in emergency department patients with chronic hepatitis C. American Journal of Emergency Medicine, 2019, 37, 286-290.	0.7	2
59	Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. Journal of Substance Abuse Treatment, 2019, 100, 45-51.	1.5	49
60	A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. Open Forum Infectious Diseases, 2019, 6, ofz166.	0.4	34
61	Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. Addictive Behaviors, 2019, 96, 56-61.	1.7	11
62	Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. American Journal of Transplantation, 2019, 19, 2329-2341.	2.6	35
63	2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection. Open Forum Infectious Diseases, 2019, 6, S886-S886.	0.4	0
64	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. American Journal of Gastroenterology, 2019, 114, 746-757.	0.2	33
65	Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014. American Journal of Medicine, 2018, 131, 669-675.	0.6	21
66	Efficacy and safety of 6 or 8Åweeks of simeprevir, daclatasvir, sofosbuvir for <scp>HCV</scp> genotype 1 infection. Journal of Viral Hepatitis, 2018, 25, 631-639.	1.0	10
67	Understanding and addressing hepatitis C reinfection in the oral directÅacting antiviral era. Journal of Viral Hepatitis, 2018, 25, 220-227.	1.0	75
68	Reply. Hepatology, 2018, 67, 1183-1184.	3.6	0
69	Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. International Journal of Drug Policy, 2018, 57, 51-60.	1.6	7
70	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clinical Infectious Diseases, 2018, 67, 1010-1017.	2.9	125
71	Directly observed therapy of sofosbuvir/ribavirin +/Å peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (CÅ<scp>DOT</scp>). Journal of Viral Hepatitis, 2018, 25, 37-46.	1.0	6
72	Utilization of hepatitis C virus RNAÅpositive donor liver for transplant to hepatitis C virus RNAÅnegative recipient. Liver Transplantation, 2018, 24, 140-143.	1.3	32

#	ARTICLE	IF	CITATIONS
73	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.	1.0	3
74	A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 284-285.	0.1	1
75	Care2Cure: A randomized controlled trial protocol for evaluating nurse case management to improve the hepatitis C care continuum within HIV primary care. <i>Research in Nursing and Health</i> , 2018, 41, 417-427.	0.8	4
76	The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States. <i>Annals of Internal Medicine</i> , 2018, 168, 702.	2.0	169
77	An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2018, 12, 101-109.	0.2	4
78	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients. <i>Annals of Internal Medicine</i> , 2018, 168, 533.	2.0	258
79	Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. <i>Transplant Infectious Disease</i> , 2018, 20, e12982.	0.7	12
80	Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 1953-1956.	2.9	0
81	Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. <i>Transplantation</i> , 2018, 102, 2088-2095.	0.5	36
82	Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw212.	1.4	9
83	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , 2017, 66, 910-918.	1.8	192
84	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , 2017, 66, 389-397.	3.6	172
85	Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 661-663.	3.6	15
86	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	1.9	2
87	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1 without cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 263-271.	1.8	261
88	Patient-reported outcomes in patients coinfected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL5 study. <i>Liver International</i> , 2017, 37, 1796-1804.	1.9	30
89	Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. <i>Hepatology</i> , 2017, 66, 1083-1089.	3.6	75
90	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	3.6	149

#	ARTICLE	IF	CITATIONS
91	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	6.1	69
92	Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. <i>American Journal of Transplantation</i> , 2017, 17, 519-527.	2.6	95
93	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 864-866.	2.9	9
94	High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. <i>Hepatology</i> , 2017, 66, 1402-1412.	3.6	39
95	Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 6-12.	2.9	133
96	Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 235-243.	2.9	15
97	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 637.	2.0	540
98	Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURWARD study). <i>Liver International</i> , 2017, 37, 836-842.	1.9	28
99	Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , 2017, 24, 280-286.	1.0	8
100	Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.. <i>Liver International</i> , 2017, 37, 1743-1744.	1.9	0
101	Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. <i>Clinical Infectious Diseases</i> , 2017, 64, 44-52.	2.9	89
102	The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. <i>Journal of Hepatology</i> , 2017, 66, 267-269.	1.8	17
103	Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. <i>Clinical Infectious Diseases</i> , 2017, 64, 92-99.	2.9	18
104	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx024.	0.4	22
105	Reply to Ozaras et al. <i>Clinical Infectious Diseases</i> , 2017, 64, 1463-1463.	2.9	4
106	Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. , 2016, 6, .		6
107	Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. , 2016, 06, .		18
108	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016, 15, 333-349.	0.6	1

#	ARTICLE	IF	CITATIONS
109	About This Continuing Medical Education Activity. <i>Clinical Infectious Diseases</i> , 2016, 63, S1-S2.	2.9	0
110	Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV. <i>AIDS Patient Care and STDs</i> , 2016, 30, 200-207.	1.1	28
111	Public health clinic-based hepatitis C testing and linkage to care in Baltimore. <i>Journal of Viral Hepatitis</i> , 2016, 23, 366-374.	1.0	51
112	Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw156.	0.4	6
113	HCV/HIV co-infected patients: no longer a "special" population?. <i>Liver International</i> , 2016, 36, 43-46.	1.9	26
114	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , 2016, 151, 1131-1140.e5.	0.6	199
115	Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw121.	0.4	12
116	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	2.9	58
117	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 528-531.	2.9	13
118	Senior Center-Based Hepatitis C Screening in Baltimore. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv217.	0.4	6
119	Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S3-S11.	2.9	49
120	Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1597-1600.	1.3	4
121	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016, 63, 437-444.	3.6	55
122	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
123	Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. <i>PLoS ONE</i> , 2016, 11, e0147879.	1.1	19
124	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31
125	Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons. <i>PLoS ONE</i> , 2015, 10, e0135882.	1.1	10
126	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	0.6	725

#	ARTICLE	IF	CITATIONS
127	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	13.9	740
128	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. <i>Lancet HIV</i> , 2015, 2, e319-e327.	2.1	285
129	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 714-725.	13.9	382
130	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 705-713.	13.9	432
131	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	3.6	82
132	Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1223.	3.8	290
133	Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1728.	3.8	85
134	Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. <i>Hepatology</i> , 2015, 62, 129-134.	3.6	23
135	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	0.6	306
136	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843.	1.0	17
137	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet</i> , 2015, 385, 1087-1097.	6.3	257
138	Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. <i>Lancet Infectious Diseases</i> , 2015, 15, 36-45.	4.6	75
139	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45.	3.6	173
140	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
141	Gastrointestinal, Hepatobiliary, and Pancreatic Manifestations of Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2015, 60, 1567-1573.		1
142	Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S42-S42.	0.4	0
143	Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care. <i>Open Forum Infectious Diseases</i> , 2014, 1, S49-S49.	0.4	1
144	Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. <i>Seminars in Liver Disease</i> , 2014, 34, 072-078.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfecting adults: Prospective analysis of 435 liver biopsy pairs. <i>Hepatology</i> , 2014, 59, 767-775.	3.6	81
146	Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719.	1.9	15
147	Management of acute and chronic HCV infection in persons with HIV coinfection. <i>Journal of Hepatology</i> , 2014, 61, S108-S119.	1.8	19
148	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 353.	3.8	236
149	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64.	3.6	43
150	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. <i>Hepatology</i> , 2014, 60, 37-45.	3.6	103
151	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Hepatology</i> , 2014, 60, 477-486.	3.6	14
152	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1483-1493.	13.9	1,241
153	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
154	Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. <i>HIV Medicine</i> , 2014, 15, 108-115.	1.0	28
155	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	1.9	62
156	Interferon-Induced Protein 10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 1881-1885.	1.9	19
157	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765.	6.3	751
158	Retreatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614.	13.9	536
159	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.	13.9	1,065
160	O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 + RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY. <i>Journal of Hepatology</i> , 2014, 60, S26.	1.8	12
161	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 597-605.	4.6	175
162	Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. <i>Hepatology</i> , 2013, 57, 2155-2163.	3.6	64

#	ARTICLE	IF	CITATIONS
163	Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. <i>Hepatology</i> , 2013, 57, 2143-2154.	3.6	102
164	Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32.	1.9	48
165	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	0.6	51
166	Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. <i>Antiviral Research</i> , 2013, 99, 214-220.	1.9	28
167	HCV therapy in HIV-infected patients. <i>Liver International</i> , 2013, 33, 63-67.	1.9	30
168	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.	3.6	67
169	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
170	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 745-760.	1.0	78
171	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	2.0	179
172	Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8.	3.8	180
173	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21.	2.0	4
174	Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2012, 54, 979-983.	2.9	27
175	Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial. <i>HIV Clinical Trials</i> , 2012, 13, 142-152.	2.0	66
176	Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3.	0.6	78
177	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. <i>Gastroenterology</i> , 2012, 143, 608-618.e5.	0.6	179
178	Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. <i>Clinical Liver Disease</i> , 2012, 1, 69-72.	1.0	0
179	Hepatitis C virus-human immunodeficiency virus coinfection. <i>Liver International</i> , 2012, 32, 129-134.	1.9	20
180	HIV Co-Infection Drug Toxicity. , 2012, , 683-699.		1

#	ARTICLE	IF	CITATIONS
181	Hepatitis C: Natural History. , 2012, , 101-105.		0
182	Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. <i>Gastroenterology</i> , 2011, 140, 809-817.	0.6	51
183	Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024.	13.9	716
184	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.	13.9	2,352
185	Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 212-223.	8.2	119
186	Racial differences in hepatitis C treatment eligibility. <i>Hepatology</i> , 2011, 54, 70-78.	3.6	47
187	Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 597-605.	0.9	26
188	ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <i>Nature</i> , 2010, 464, 405-408.	13.7	430
189	Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. <i>American Journal of Gastroenterology</i> , 2010, 105, 989-1004.	0.2	30
190	Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. <i>Aids</i> , 2010, 24, 811-817.	1.0	9
191	MELD Score Is an Important Predictor of Pretransplantation Mortality in HIV-Infected Liver Transplant Candidates. <i>Gastroenterology</i> , 2010, 138, 159-164.	0.6	77
192	Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. <i>Gastroenterology</i> , 2010, 139, 1602-1611.e1.	0.6	102
193	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	0.6	633
194	Assessment of Liver Fibrosis by Transient Elastography in Persons with Hepatitis C Virus Infection or HIV–Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2009, 48, 963-972.	2.9	134
195	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. <i>Nature</i> , 2009, 461, 399-401.	13.7	3,394
196	Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2009, 361, 580-593.	13.9	1,166
197	Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2009, 360, 1827-1838.	13.9	1,038
198	Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. <i>Aids</i> , 2009, 23, 2397-2404.	1.0	55

#	ARTICLE	IF	CITATIONS
199	Viral hepatitis and HIV coinfection. <i>Journal of Hepatology</i> , 2008, 48, 353-367.	1.8	260
200	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	1.0	149
201	Management of Hepatic Complications in HIV-Infected Persons. <i>Journal of Infectious Diseases</i> , 2008, 197, S279-S293.	1.9	73
202	The HIV-Coinfected Patient. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, S36-S37.	0.9	10
203	Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007, 21, 1073-1089.	1.0	295
204	Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. <i>Aids</i> , 2007, 21, 2209-2216.	1.0	169
205	Therapeutic issues in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 371-386.	1.0	71
206	Specific targeted antiviral therapy for hepatitis C. <i>Current Gastroenterology Reports</i> , 2007, 9, 5-13.	1.1	19
207	Hepatitis C virus infection in HIV-infected patients. <i>Current Infectious Disease Reports</i> , 2007, 3, 469-476.	1.3	21
208	Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. <i>Journal of Hepatology</i> , 2006, 44, S49-S55.	1.8	20
209	Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. <i>Aids</i> , 2006, 20, 2361-2369.	1.0	121
210	Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. <i>Journal of Viral Hepatitis</i> , 2006, 13, 683-689.	1.0	112
211	Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. <i>Hepatology</i> , 2006, 43, 1317-1325.	3.6	3,343
212	Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. <i>Aids</i> , 2005, 19, S8-S12.	1.0	17
213	Hepatic steatosis and antiretroviral drug use among adults coinfecting with HIV and hepatitis C virus. <i>Aids</i> , 2005, 19, 585-592.	1.0	158
214	Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 214-224.	2.3	33
215	The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. <i>Hepatology</i> , 2005, 41, 123-131.	3.6	112
216	Epidemiology and Natural History of Hepatitis C Virus Infection in Injection Drug Users: Implications for Treatment. <i>Clinical Infectious Diseases</i> , 2005, 40, S263-S269.	2.9	43

#	ARTICLE	IF	CITATIONS
217	Therapy Insight: management of hepatitis C in patients coinfectd with HIV. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 223-231.	1.7	1
218	Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 504-506.	0.9	35
219	Management of the Hematologic Complications of Hepatitis C Therapy. Clinics in Liver Disease, 2005, 9, 601-616.	1.0	40
220	Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. Journal of Hepatology, 2005, 43, 78-84.	1.8	200
221	Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors. Clinical Infectious Diseases, 2004, 38, S90-S97.	2.9	186
222	Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2004, 11, 243-250.	1.0	139
223	Hepatitis C virus infection in HIV-infected patients. Current HIV/AIDS Reports, 2004, 1, 128-135.	1.1	11
224	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology, 2004, 40, 1450-1458.	3.6	136
225	Epoetin alfa maintains hemoglobin levels in HCV-infected patients: a prospective, double-blind, randomized controlled study1 The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Br��u, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor University Medical Center, Dallas, Texas; and Robert S. Brown, M.D., Cleveland Clinic Foundation, Cleveland, Ohio. JAMA - Journal of the American Medical Association, 2004, 291, 1315-1321.	0.6	548
226	Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 464-472.	0.9	21
227	Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Aids, 2004, 18, 2277-2284.	1.0	143
228	Care of patients with hepatitis C and HIV co-infection. Aids, 2004, 18, 1-12.	1.0	194
229	Hepatitis C in the HIV-infected patient. Clinics in Liver Disease, 2003, 7, 179-194.	1.0	50
230	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology, 2003, 98, 2491-2499.	0.2	208
231	Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors. Seminars in Liver Disease, 2003, 23, 183-194.	1.8	80
232	The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 577-584.	0.9	88
233	Hepatitis C in the HIV-Infected Person. Annals of Internal Medicine, 2003, 138, 197.	2.0	348
234	Needlestick Transmission of Hepatitis C. JAMA - Journal of the American Medical Association, 2002, 287, 2406.	3.8	98

#	ARTICLE	IF	CITATIONS
235	Hepatitis C and Progression of HIV Disease. JAMA - Journal of the American Medical Association, 2002, 288, 199.	3.8	393
236	Peginterferon-??-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C. BioDrugs, 2002, 16, 105-109.	2.2	5
237	Treatment of chronic hepatitis C: A systematic review. Hepatology, 2002, 36, S135-S144.	3.6	76
238	Hepatitis C virus infection in HIV-infected patients. Current Hepatitis Reports, 2002, 1, 16-22.	0.3	1
239	Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 2002, 35, 182-189.	3.6	436
240	Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports, 2001, 3, 469-476.	1.3	31
241	Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology, 2001, 33, 1554-1554.	3.6	54
242	Hepatitis C Virus Infection in HIV-infected Patients. Current Infectious Disease Reports, 2001, 3, 469-476.	1.3	18
243	Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2000, 30, S77-S84.	2.9	244
244	Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. JAMA - Journal of the American Medical Association, 2000, 283, 74.	3.8	822
245	The Effect of Acute Infectious Illnesses on Plasma Human Immunodeficiency Virus (HIV) Type 1 Load and the Expression of Serologic Markers of Immune Activation among HIVâ€infectd Adults. Journal of Infectious Diseases, 1998, 178, 1642-1648.	1.9	105
246	HIV and hepatitis C virus co-infection. The Hopkins HIV Report: A Bimonthly Newsletter for Healthcare Providers, 1998, 10, 8, 12.	0.0	2